Neoadjuvant Tislelizumab in Combination With Nab-Paclitaxel for UTUC

Clinical trial NCT07126119 · RECRUITING

Trial details

NCT number: NCT07126119
Sponsor: Tianjin Medical University Second Hospital
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Upper Tract Urothelial Carcinoma Neoadjuvant Therapy PD-1 Inhibitor Nab-paclitaxel

Start date: 2025-07-05
Primary completion: 2026-12-30
Enrollment: 35

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.